SetPoint Medical
SetPoint Medical, founded in 2007, is developing a novel platform to stimulate the vagus nerve for treating autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease.
History of SetPoint Medical
SetPoint Medical was founded in 2007. The company is located in Santa Clarita Valley, just north of Los Angeles in the Southern California Innovation Park. Since its inception, the company has focused on developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex, intending to produce a systemic immune-restorative effect.
SetPoint Medical's Platform Technology
SetPoint Medical's platform technology is designed to offer treatment alternatives for rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions. The small, self-contained nerve stimulator generates precise electrical pulses using an integrated circuit, telemetry hardware, and a rechargeable battery enclosed in a ceramic and titanium case. The device is programmed to deliver therapy automatically on a preset schedule by stimulating the vagus nerve once daily, aiming to activate the inflammatory reflex for a systemic immune-restorative effect.
Clinical Studies and FDA Designations
SetPoint Medical has completed three proof-of-concept and feasibility clinical studies to evaluate the safety and effectiveness of vagus nerve stimulation for treating rheumatoid arthritis and Crohn's disease. The company is currently conducting an approximately 250-patient randomized, double-blind study to assess its device's efficacy in treating rheumatoid arthritis in adults with inadequate responses or intolerance to RA medications. SetPoint Medical's device has been granted FDA Breakthrough Device Designation for rheumatoid arthritis and neuroimmune modulation platform for multiple sclerosis treatment.
Recent Financing and Investments
In its recent financial development, SetPoint Medical announced an $80 million preferred stock financing. This financing round was co-led by new investors Norwest Venture Partners and Viking Global Investors. These investments are expected to support further clinical trials and the development of SetPoint Medical's innovative platform technology.
Medical Applications of SetPoint Medical's Technology
SetPoint Medical's device uses precise vagus nerve stimulation to activate innate anti-inflammatory and immune-restorative pathways, targeting inflammation-mediated autoimmune conditions. Beyond rheumatoid arthritis, the platform has been featured in successful proof-of-concept studies for Crohn’s disease and has shown promising pre-clinical research outcomes for multiple sclerosis. The technology aims to provide a less risky and more cost-effective alternative to drug therapy by activating the body's immunomodulatory pathways through targeted electrical stimulation.